Company Reports

Recent Updates

All Reports

Stock Analyst Note

Having spent some time researching what the current market price of Ageas implies, how those assumptions compare with management's current Elevate27 strategic targets, and what we think is achievable long-term for the business, we believe Ageas is currently undervalued.
Company Report

Ageas would do well to take a leaf out of other midsize European multiline books by clearing up its financial statements and concentrating on core markets. Ageas has strength in its domestic market of Belgium, evolving to be the market leader, and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are lower margin but capital-light. This is probably one of the reasons behind the company’s gradual improvement in return on equity. Investments have played a part in improving customer service and protection that can be sold with savings products, and this creates a stickier set of customers and products. These investments have oriented around improving standards of underwriting, and despite raising expenses, the net effect in nonlife insurance has been positive. Ageas has a leading health insurance business, with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Stock Analyst Note

On Aug. 3, Ageas announced the divestment of its 30.95% stake in Etiqa, or Malayan Banking Berhad, to Maybank for a cash consideration of EUR 1.1 billion.
Company Report

Ageas would do well to take a leaf out of other midsize European multiline books by clearing up its financial statements and concentrating on core markets. Ageas has strength in its domestic market, Belgium, evolving to be the market leader, and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are lower margin but capital-light. This is probably one of the reasons behind the company’s gradual improvement in return on equity. Investments have played a part in improving customer service and protection that can be sold with savings products, and this creates a stickier set of customers and products. These investments have oriented around improving standards of underwriting, and despite raising expenses, the net effect in nonlife insurance has been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Company Report

Ageas would do well to take a leaf out of other midsize European multiline books by clearing up its financial statements and concentrating on core markets. Ageas has strength in its domestic market, Belgium, evolving to be the market leader, and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are lower margin but capital-light. This is probably one of the reasons behind the company’s gradual improvement in ROEs. Investments have played a part in improving customer service and protection that can be sold with savings products, and this creates a stickier set of customers and products. These investments have oriented around improving standards of underwriting, and despite raising expenses, the net effect in nonlife insurance has been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Stock Analyst Note

With the UK changing prime minister for the seventh time in 10 years and it looking increasingly likely Andy Burnham will be the leader of the Labour Party and prime minister, transport—one of his key areas of focus as mayor of Manchester—could continue as an area of focus.
Company Report

Ageas would do well to take a leaf out of other midsize European multiline books, clear up its financial statements, and concentrate on core markets. Ageas has strength in its domestic market, Belgium, evolving to be the market leader, and is a dominant force in long-term savings. Its strategy in this line is to continue with the shift to unit-linked products that are capital-light despite lower margins. This is probably one of the reasons behind the company’s gradual improvement in ROEs. Investments have played a part in improving customer service and protection products that can be sold with savings products, and this creates a stickier set of products and customers. These investments have been oriented around improving standards of underwriting, and despite raising expenses, the net effect in nonlife insurance has been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Stock Analyst Note

For the full year 2025, Ageas has delivered good operational results. However, the company's performance looks lackluster with regard to the generation of operational capital. The results build on a good first half and are underpinned by a period of acquisitions.
Company Report

Ageas would do well to take a leaf out of other midsize European multiline books, clear up its financial statements, and concentrate on core markets. Ageas has strength in its domestic market, Belgium, evolving to be the market leader, and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are capital-light despite lower margins. This is probably one of the reasons behind the company’s gradual improvement in ROEs. Investments have played a part in improving customer service and protection products that can be sold with savings products, and this creates a stickier set of products and customers. These investments have oriented around improving standards of underwriting, and despite raising expenses, the net effect in nonlife insurance has been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Stock Analyst Note

For first-half 2025, Ageas has delivered a convincing beat versus company-compiled consensus with EUR 734 million in net operating profit. This positions Ageas well versus the EUR 1.30 billion to EUR 1.35 billion 2025 target that we think should equate to more than EUR 1.1 billion net profit.
Stock Analyst Note

In our look into European dividends for companies and stocks we prefer for 2025 earnings, we like Admiral, Munich, and Scor, but we prefer Scor over Munich based on its price/fair value ratio. We also think there is potential in Ageas.
Company Report

Ageas would do well to take a leaf out of other midsize European multiline books, clear up its financial statements, and concentrate on core markets. Ageas has strength in its domestic market, Belgium, evolving to be the market leader and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are capital-light despite lower margins. This is probably one of the reasons behind the company’s gradual improvement in ROEs. Investments have played a part in improving customer service and protection offerings that can be sold into savings products, and this creates a stickier set of products and customers. These investments have oriented around improving standards of underwriting, and despite raising expenses, the net effect in nonlife insurance has been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Company Report

Ageas would do well to take a leaf out of other mid-sized European multi-line books, clear up its financial statements and concentrate on core markets. Ageas has strength in its domestic market Belgium, evolving to be the market leader and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are capital-light despite lower margins. This is probably one of the reasons behind the company’s gradual improvement in ROEs. Investments have played a part in improving customer service and protection offerings that can be sold into savings products, and this creates a sticker set of products and customers. These investments have oriented around improving standards of underwriting, and despite raising expenses the net effect in nonlife insurance have been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.
Stock Analyst Note

With net operating profit of EUR 1.240 billion, Ageas delivered earnings for full-year 2024 that are fairly in line with company-compiled consensus. However, we think the price of the CASHES has continued to climb with the price of Ageas' shares, and this is clouding the business.
Company Report

Ageas is an improving business. However, it would do well to take a leaf out of other mid-sized European multiline books, clear up its financial statements, and concentrate on core markets. Ageas has clear strength in its domestic market Belgium, evolving to be the market leader and is a dominant force in long-term savings. Its strategy in this line is to continue with the ongoing shift to unit-linked products that are capital-light despite lower margins. This is probably one of the reasons behind the company’s gradual but upward improvement in ROEs. Investments have played a decent part in improving customer service and protection offerings that can be sold into savings products, and this creates a sticker set of products and customers. These investments have oriented around improving standards of underwriting, and despite raising expenses the net effect in nonlife insurance have been positive. Ageas has a leading health insurance business with expenditure on health in Belgium being one of the highest in Europe. The firm targets price stability and ambulatory care services.

Sponsor Center